US Bancorp DE increased its stake in Core Laboratories NV (NYSE:CLB) by 2.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 133,795 shares of the company’s stock after buying an additional 2,856 shares during the period. US Bancorp DE owned approximately 0.30% of Core Laboratories NV worth $15,030,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Emerald Acquisition Ltd. bought a new stake in Core Laboratories NV during the second quarter worth $110,515,000. Royal Bank of Canada increased its stake in Core Laboratories NV by 416.8% in the second quarter. Royal Bank of Canada now owns 475,077 shares of the company’s stock worth $58,857,000 after buying an additional 383,153 shares during the last quarter. APG Asset Management N.V. increased its stake in Core Laboratories NV by 283.8% in the third quarter. APG Asset Management N.V. now owns 339,287 shares of the company’s stock worth $38,112,000 after buying an additional 250,889 shares during the last quarter. Mar Vista Investment Partners LLC increased its stake in Core Laboratories NV by 112.0% in the third quarter. Mar Vista Investment Partners LLC now owns 417,956 shares of the company’s stock worth $46,949,000 after buying an additional 220,836 shares during the last quarter. Finally, Fiera Capital Corp bought a new stake in Core Laboratories NV during the second quarter worth $26,853,000.

Institutional Ownership by Quarter for Core Laboratories NV (NYSE:CLB)

Shares of Core Laboratories NV (NYSE:CLB) traded down 0.774% during trading on Monday, reaching $108.395. 118,844 shares of the company were exchanged. The stock’s 50 day moving average is $105.82 and its 200 day moving average is $114.55. The company has a market capitalization of $4.78 billion, a price-to-earnings ratio of 73.438 and a beta of 1.40. Core Laboratories NV has a 1-year low of $84.50 and a 1-year high of $135.49.

Core Laboratories NV (NYSE:CLB) last announced its earnings results on Wednesday, October 19th. The company reported $0.38 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.38. Core Laboratories NV had a net margin of 10.17% and a return on equity of 108.46%. The business earned $143.50 million during the quarter, compared to analysts’ expectations of $155.72 million. During the same period in the prior year, the company earned $0.83 earnings per share. The firm’s revenue was down 27.3% on a year-over-year basis. Equities analysts anticipate that Core Laboratories NV will post $1.52 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, November 22nd. Stockholders of record on Friday, October 21st were paid a $0.55 dividend. The ex-dividend date was Wednesday, October 19th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.01%. Core Laboratories NV’s dividend payout ratio (DPR) is presently 149.66%.

COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this report on another publication, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this report can be read at https://www.thecerbatgem.com/2016/11/28/core-laboratories-nv-clb-shares-bought-by-us-bancorp-de.html.

A number of research firms recently weighed in on CLB. Credit Suisse Group AG began coverage on Core Laboratories NV in a report on Thursday, September 1st. They issued a “neutral” rating and a $115.00 price objective for the company. Zacks Investment Research raised shares of Core Laboratories NV from a “sell” rating to a “hold” rating in a research report on Thursday, October 6th. DA Davidson began coverage on shares of Core Laboratories NV in a research report on Wednesday, October 5th. They set a “buy” rating and a $136.00 price objective on the stock. Citigroup Inc. increased their price objective on shares of Core Laboratories NV from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 11th. Finally, Cowen and Company reissued a “market perform” rating and set a $105.00 price objective on shares of Core Laboratories NV in a research report on Saturday, October 22nd. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $121.50.

About Core Laboratories NV

Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.

5 Day Chart for NYSE:CLB

Receive News & Stock Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related stocks with our FREE daily email newsletter.